Multiple inhibitors targeting PI3K, AKT, RAF and MEK are under development for cancer therapy, but early-phase clinical trials suggest that the single agent efficiency of such inhibitors seems to be limited, except in the case of the Raf mutant melanoma, where both RAF and MEK inhibitors have high clinical activity. This evidence concerns the gene AKT1 and melanoma.